314 related articles for article (PubMed ID: 21883604)
21. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
22. Gender differences in circumstances surrounding first injection experience of rural injection drug users in the United States.
Young AM; Larian N; Havens JR
Drug Alcohol Depend; 2014 Jan; 134():401-405. PubMed ID: 24216393
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of injection drug users derived from a large family study of alcoholism.
Dinwiddie SH
Compr Psychiatry; 1997; 38(4):218-29. PubMed ID: 9202879
[TBL] [Abstract][Full Text] [Related]
24. Illicit use of methadone and buprenorphine among adolescents and young adults in Sweden.
Richert T; Johnson B
Harm Reduct J; 2013 Oct; 10():27. PubMed ID: 24139199
[TBL] [Abstract][Full Text] [Related]
25. Coping and emotion regulation profiles as predictors of nonmedical prescription drug and illicit drug use among high-risk young adults.
Wong CF; Silva K; Kecojevic A; Schrager SM; Bloom JJ; Iverson E; Lankenau SE
Drug Alcohol Depend; 2013 Sep; 132(1-2):165-71. PubMed ID: 23453258
[TBL] [Abstract][Full Text] [Related]
26. Trends in controlled-release oxycodone (OxyContin) prescribing among Medicaid recipients in Kentucky, 1998-2002.
Havens JR; Talbert JC; Walker R; Leedham C; Leukefeld CG
J Rural Health; 2006; 22(3):276-8. PubMed ID: 16824176
[TBL] [Abstract][Full Text] [Related]
27. Emergence of wasp dope in rural Appalachian Kentucky.
Young AM; Livingston M; Vickers-Smith R; Cooper HLF
Addiction; 2021 Jul; 116(7):1901-1907. PubMed ID: 33063438
[TBL] [Abstract][Full Text] [Related]
28. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
Cheng HG; Coplan PM
Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
[TBL] [Abstract][Full Text] [Related]
29. Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population.
Martins SS; Storr CL; Zhu H; Chilcoat HD
Drug Alcohol Depend; 2009 Jan; 99(1-3):58-67. PubMed ID: 18706774
[TBL] [Abstract][Full Text] [Related]
30. Transition to injection drug use: the role of initiators.
Rotondi NK; Strike C; Kolla G; Rotondi MA; Rudzinski K; Guimond T; Roy E
AIDS Behav; 2014 Mar; 18(3):486-94. PubMed ID: 24398591
[TBL] [Abstract][Full Text] [Related]
31. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
Cicero TJ; Inciardi JA; Muñoz A
J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
[TBL] [Abstract][Full Text] [Related]
32. Prescription OxyContin abuse among patients entering addiction treatment.
Carise D; Dugosh KL; McLellan AT; Camilleri A; Woody GE; Lynch KG
Am J Psychiatry; 2007 Nov; 164(11):1750-6. PubMed ID: 17974941
[TBL] [Abstract][Full Text] [Related]
33. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation.
Wolff C; Dowd WN; Ali MM; McClellan C; Meinhofer A; Glos L; Mutter R; Rosenberg M; Schick A
Addict Behav; 2020 Jun; 105():106268. PubMed ID: 32036188
[TBL] [Abstract][Full Text] [Related]
34. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions.
Cone EJ; Fant RV; Rohay JM; Caplan YH; Ballina M; Reder RF; Haddox JD
J Anal Toxicol; 2004 Oct; 28(7):616-24. PubMed ID: 15516322
[TBL] [Abstract][Full Text] [Related]
35. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions.
Cone EJ; Fant RV; Rohay JM; Caplan YH; Ballina M; Reder RF; Haddox JD
J Anal Toxicol; 2004; 28(4):217-25. PubMed ID: 15189671
[TBL] [Abstract][Full Text] [Related]
36. An exploratory study of OxyContin use among individuals with substance use disorders.
Levy MS
J Psychoactive Drugs; 2007 Sep; 39(3):271-6. PubMed ID: 18159780
[TBL] [Abstract][Full Text] [Related]
37. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study.
Carlson RG; Nahhas RW; Martins SS; Daniulaityte R
Drug Alcohol Depend; 2016 Mar; 160():127-34. PubMed ID: 26785634
[TBL] [Abstract][Full Text] [Related]
38. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
39. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013.
Jones CM; Muhuri PK; Lurie PG
Clin J Pain; 2017 May; 33(5):452-461. PubMed ID: 27513641
[TBL] [Abstract][Full Text] [Related]
40. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
